FinDec Wealth Services’s Cardiff Oncology CRDF Stock Holding History

FinDec Wealth Services’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,000	Closed	-$25.9K	–	34
2026 Q1	$25.9K	Hold	16,000	–	–	0.03%	30
2025 Q4	$45K	Hold	16,000	–	–	0.05%	32
2025 Q3	$33K	Hold	16,000	–	–	0.03%	34
2025 Q2	$50.4K	Hold	16,000	–	–	0.05%	35
2025 Q1	$50.2K	Hold	16,000	–	–	0.05%	38
2024 Q4	$69.4K	Hold	16,000	–	–	0.05%	39
2024 Q3	$42.7K	Hold	16,000	–	–	0.02%	42
2024 Q2	$35.5K	Hold	16,000	–	–	0.02%	41
2024 Q1	$85.4K	Hold	16,000	–	–	0.05%	43
2023 Q4	$23.7K	Hold	16,000	–	–	0.02%	43
2023 Q3	$22.2K	Hold	16,000	–	–	0.02%	43
2023 Q2	$23.5K	Hold	16,000	–	–	0.02%	44
2023 Q1	$26.4K	Hold	16,000	–	–	0.02%	42
2022 Q4	$22.4K	Buy	+16,000	New	+$22.9K	0.02%	40

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

FinDec Wealth Services's CRDF Position: Q2 2026 in Review

FinDec Wealth Services sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 16,000 shares — an estimated $25.9K sold.

FinDec Wealth Services first reported a position in CRDF in Q4 2022 and held it in 14 quarters. The position peaked at $85.4K in Q1 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

FinDec Wealth Services reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
FinDec Wealth Services sold 16,000 Cardiff Oncology shares in Q2 2026, an estimated $25.9K.
FinDec Wealth Services first reported a position in Cardiff Oncology in Q4 2022 and held it in 14 quarters.
FinDec Wealth Services's Cardiff Oncology position peaked at $85.4K in Q1 2024.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on FinDec Wealth Services's 13F filing for Q2 2026, filed 6 Aug 2026.